Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
vaccines to protect people from serious bacterial infectious diseases. While Vaxcyte is still a clinical-stage company, Wall Street seems highly optimistic about PCVX stock, rating it as a consensus “Strong Buy” and forecasting potential upside of 76% from current levels based on the average price target of $109. Vaxcyte is even attracting long-term growth investors' interest. This small-cap biotech is up 35% so far this year, outperforming many Big Tech names. More News from Barchart Nvidia Stock May Be Oversold - What is the Best NVDA Play? Jobs, Geopolitics and Other Key Things to Watch this Week Nvidia Stock Forecast: Could NVDA Stock Rise To $300 in 2026? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Let's find out whether it is the right time to grab PCVX stock now. www.barchart.com What Is So Enticing About Vaxcyte? Wall Street's enthusiasm stems from a rare combination of late-stage momentum, diffe
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte's VAX-31 Shift the Bull Case (PCVX)? [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists [Yahoo! Finance]Yahoo! Finance
- A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum Rebuilds [Yahoo! Finance]Yahoo! Finance
- Vaxcyte, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Vaxcyte (PCVX) had its "buy" rating reaffirmed by BTIG Research.MarketBeat
PCVX
Earnings
- 2/24/26 - Miss
PCVX
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- PCVX's page on the SEC website